Safety and Use of Cefpodoxime‑Clavulanate in Pregnancy

Cephalosporin Safety in Pregnancy

The European Respiratory Society and the Thoracic Society of Australia & New Zealand classify cephalosporins (including cefuroxime and other agents) as “Compatible” for use throughout pregnancy, based on human data showing no teratogenicity at standard therapeutic doses. 1
In the first and second trimesters, cephalosporins may be prescribed when clinically indicated because they have not been associated with fetal malformations. 2

Amoxicillin‑clavulanate is not recommended for women at risk of preterm delivery because of a very low but documented association with fetal necrotizing enterocolitis. This recommendation stems from expert consensus within the European Respiratory Society guidelines. 3
Although amoxicillin‑clavulanate is classified as TGA Category B1 and FDA Category B and labeled “Compatible” for pregnancy, exposure during organogenesis carries a very low risk of oral clefts. The risk assessment is based on limited observational evidence. 3

First & Second Trimester: Use of cefpodoxime‑clavulanate is acceptable when the maternal infection warrants therapy, given the lack of teratogenic effects from the cephalosporin component. 1
Third Trimester / Near Delivery: Exercise caution and evaluate the risk of preterm labor before prescribing the clavulanate‑containing combination; consider avoiding it in high‑risk patients. 3

When beta‑lactamase inhibition is not essential, cefpodoxime alone may be used as a safer alternative (no specific citation required).
Other cephalosporins such as cefuroxime (classified as Category B1 and “Compatible”) are acceptable substitutes for cefpodoxime‑clavulanate in pregnant patients. 2

Systemic antibiotics, including cephalosporins and amoxicillin‑clavulanate, are excreted into breast milk and can potentially lead to false‑negative bacterial cultures in febrile infants or alter intestinal flora, but they do not usually require cessation of breastfeeding. 1

Do not withhold necessary antibiotic therapy for maternal infection; untreated maternal disease poses a greater risk to the fetus than the modest potential drug‑related hazards. 4
Assess preterm‑delivery risk before initiating clavulanate‑containing regimens in the third trimester to prevent possible neonatal complications. 3
Balance maternal benefit against fetal risk—the consensus is that the fetal danger from uncontrolled maternal infection generally outweighs the low‑level risks associated with appropriate antibiotic use. 5